Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
A Real-World Prospective Study of Mother-to-Child Transmission of Hepatitis B Virus in China Using a Mobile Health Application (Shield 01)
36 Pages Posted: 3 May 2019
More...Abstract
Background: The World Health Organization (WHO) has set a goal of eliminating viral hepatitis as public health threat by 2030. To assess feasibility of this goal in China, we carried out a real-world study to determine whether WHO's goal could be achieved.
Methods: One thousand and eight hepatitis B surface antigen (HBsAg) positive pregnant women were enrolled at ten hospitals. Immunoprophylaxis was routinely administered to infants. In addition, mothers with HBV DNA level > 2,000,000 IU per milliliter were advised to initiate antiviral therapy during late pregnancy. A health application called SHIELD was used to manage the study.
Findings: Nine hundred and five of enrolled mothers with 924 infants completed the follow-up, including 561 hepatitis B e antigen (HBeAg) positive mothers and 499 mothers with HBV DNA level > 2,000,000 IU per milliliter. There were 446 mothers who received antiviral therapy, including 72·3% of the mothers with HBV DNA level > 2,000,000 IU per millilitre and 21·0% of the mothers with HBV DNA level of < 2,000,000 IU per millilitre. Birth-dose hepatitis B vaccine (HepB) and hepatitis B immunoglobulin (HBIG) were received by 99·9% and 99·8% of infants within 24 hours after birth, respectively. Eight infants became infected with HBV. The overall rate of mother-to-child transmission (MTCT) was 0·9% (95% confidence interval, 0·4% to 1·7%). Birth defects were rare (0·5% among infants with maternal antiviral exposure versus 0·7% among infants without exposure; P=1·00).
Interpretation: In real-world practice, there was a low rate (<1%) of MTCT with administration of combined immunoprophylaxis to infants, and initiation of maternal antiviral therapy during pregnancy among a subset of mothers with high HBV viral load. This study suggested that a comprehensive management composing of immunoprophylaxis to infants and antiviral prophylaxis to mothers was a feasible strategy in China which may accelerate achieving the WHO goal of eliminating the MTCT of HBV.
Funding: This work was funded by China Foundation for Hepatitis Prevention and Control (CFHPC) and National Natural Science Foundation of China (Grant No.81673243).
Declaration of Interest: JH is a consultant for AbbVie, Arbutus, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, and Roche, and received grants from Bristol Myers Squibb, Johnson & Johnson, and Gilead science, all outside the submitted work. The remaining authors declare no competing interests.
Ethical Approval: The study protocol was approved by the ethics committee at each participating centre.
Suggested Citation: Suggested Citation